Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Family Medicine
Atherosclerosis Clinical Trials
A listing of Atherosclerosis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Birmingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Birmingham : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Fairhope : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Huntsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Huntsville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mobile : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Alaska
Anchorage : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Anchorage : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Arizona
Bullhead City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Glendale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Phoenix : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Scottsdale : Scottsdale Healthcare Shea
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Arkansas
Hot Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jonesboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Little Rock : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
California
Santa Ana : Coastal Multi-Specialty Research
Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.
View More »
Carmichael : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Concord : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Escondido : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fullerton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Glendale : GSK Investigational Site
To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers
Huntington Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lancaster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Loma Linda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lomita : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Long Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Los Angeles : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Los Angeles : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Los Angeles : University of Southern California
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Los Gatos : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Madera : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mission Viejo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Northridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oakland : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Oceanside : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orangevale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palm Spring : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palm Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pasadena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pomona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Poway : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Redondo Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sacramento : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sacramento : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Diego : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Diego : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Francisco : San Francisco Veterans Affairs Medical Center
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
San Ramon : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Santa Ana : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Ana : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Santa Clara : Abbott Vascular
The ABSORB BTK (Below The Knee) Clinical Investigation
Santa Rosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Spring Valley : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Temecula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Torrance : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Torrance : Los Angeles Biomedical Research Institute
Effect of Aged Garlic Extract on Atherosclerosis
Tustin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Visalia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vista : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Walnut Creek : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Westlake Village : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Colorado
Aurora : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Colorada Springs : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Denver : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Denver : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Golden : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Longmount : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Thornton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Connecticut
Bridgeport : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hartford : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Delaware
Newark : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Newark : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
District of Columbia
Washington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florida
Atlantis : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Clearwater : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Daytona Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Defuniak Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Doral : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Gainesville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hollywood : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jacksonville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jacksonville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Jacksonville Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jacksonville Beach : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Jupiter : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Miami : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Miami : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Miami Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Naples : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ocala : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Orlando : GSK Investigational Site
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
Pinellas Park : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ponte Verda : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Port Charlotte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Port Orange : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sarasota : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Miami : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tallahassee : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tampa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wellington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Georgia
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Atlanta : Piedmont Heart Institute
Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program
Augusta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austell : Wellstar Cobb Hospital
SuperNOVA Clinical Stenting Trial
Conyers : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Covington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cumming : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Decatur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gainesville : Northeast Georgia Heart Center
The eMESH 1 Feasibility Study
Macon : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roswell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hawaii
Honolulu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Idaho
Coeur D Alene : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Illinois
Aurora : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chicago : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chicago : Northwestern University
Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Chicago : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Jerseyville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Lombard : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Melrose Park : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Oak Lawn : Advocate Christ Medical Center
SuperNOVA Clinical Stenting Trial
Peoria : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Peoria : St. Francis Medical Center
SuperNOVA Clinical Stenting Trial
Indiana
Anderson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Avon : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Evansville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Franklin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ft. Wayne : Parkview Hospital
SuperNOVA Clinical Stenting Trial
View More »
Greenfield : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Indianapolis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Indianapolis : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Valparaiso : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Iowa
Ames : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Iowa City : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Waterloo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
West Des Moines : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kansas
Wichita : Via Christi Research
CANTOS: Cardiovascular Risk Reduction Study
View More »
Kansas City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Overland Park : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Topeka : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wichita : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kentucky
Crestview Hills : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Louisville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Louisville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Owensboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Louisiana
Baton Rouge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Covington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Houma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lafayette : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lafayette : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Mandeville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Metairie : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Iberia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
New Orleans : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Orleans : Ochsner Clinic Foundation
SuperNOVA Clinical Stenting Trial
Opelousas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shreveport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slidell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slidell : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Winnsboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zachary : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Maine
Auburn : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bangor : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Beltsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Scarborough : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Maryland
Towson : Spectrum Clinical Research, Inc.
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)
Towson : Spectrum Clinical Research, Inc.
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)
View More »
Baltimore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Baltimore : Sinai Center for Thrombosis Research
Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis
Baltimore : Frederick Memorial Hospital
SuperNOVA Clinical Stenting Trial
Baltimore : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lutherville Timonium : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oxon Hill : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rockville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Massachusetts
Boston : Massachusetts General Hospital
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Boston : Massachusetts General Hospital
Subclinical Atherosclerosis in HIV-infected Patients
Boston : Beth Israel Deaconess Medical Center
SuperNOVA Clinical Stenting Trial
Boston : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Burlington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Fall River : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haverhill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hyannis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Natick : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Michigan
Ann Arbor : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cadillac : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chelsea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Detroit : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kalamazoo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Midland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Novi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petoskey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petoskey : Northern Michigan Hospital
SuperNOVA Clinical Stenting Trial
Petoskey : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Royal Oak : William Beaumont Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Saginaw : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Troy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wyoming : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Minnesota
Duluth : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Edina : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Minneapolis : GSK Investigational Site
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
Minneapolis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Robbinsdale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Rochester : Mayo Clinic Updated
Assessment of Coronary Plaque Composition Using Optical Coherence Tomography
Rochester : Mayo Clinic
Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III
Saint Paul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Cloud : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Cloud : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mississippi
Hattiesburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Picayune : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Missouri
Chesterfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kansas City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint Louis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Springfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
St Louis : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
St. Louis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nebraska
Grand Island : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Grand Island : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lincoln : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Omaha : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nevada
Las Vegas : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
New Hampshire
New Jersey
Browns Mills : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Camden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Elizabeth : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Freehold : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haddon Heights : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
New Brunswick : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ocean : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pomona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
West Orange : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
New Mexico
Albuquerque : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Albuquerque : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
New York
Binghamton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Buffalo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Endwell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liverpool : St. Joseph's Hospital Health Center
SuperNOVA Clinical Stenting Trial
Mineola : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
New York : Mount Sinai School of Medicine Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
New York : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New York : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
New York : Mount Sinai Medical Center
SuperNOVA Clinical Stenting Trial
New York : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rochester : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Westfield : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Williamsville : 115 Flint Road
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
Williamsville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
North Carolina
Raleigh : Rex Healthcare
ALERTS (AngeLmed for Early Recognition and Treatment of STEMI) Study
Raleigh : Rex Healthcare
TRANSLATE- Treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Registry
View More »
Asheboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Calabash : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charlotte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charlotte : Mid-Carolina Cardiology Presbyterian Hospital
SuperNOVA Clinical Stenting Trial
Charlotte : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Durham : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gastonia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Greensboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hickory : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Matthews : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pinehurst : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salisbury : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salisbury : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sanford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Statesville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Statesville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tabor City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wilmington : New Hanover Regional Medical Center
SuperNOVA Clinical Stenting Trial
Wilmington : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Winston Salem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
North Dakota
Fargo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Grand Forks : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ohio
Akron : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cincinnati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cincinnati : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Cincinnati : Metabolic And Atherosclerosis Research Center Updated
Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins
Cincinnati : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Cleveland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbus : Ohio State University
Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE)
Columbus : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbus : Grant Medical Center
SuperNOVA Clinical Stenting Trial
Columbus : Ohio State University Medical Center
SuperNOVA Clinical Stenting Trial
Elyria : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Garfield Heights : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Marion : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Middleburg Heights : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sandusky : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Toledo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Westlake : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Oklahoma
Bartlesville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oklahoma City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oklahoma City : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tulsa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oregon
Bend : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pennsylvania
Abington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Allentown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Altoona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beaver : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beaver : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Camp Hill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Danville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Doylestown : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Erie : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Harrisburg : Pinnacle Health Cardiovascular Insititute
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Hershey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jersey Shore : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lewistown : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Philadelphia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pittsburgh : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pittsburgh : UPMC - Passavant
SuperNOVA Clinical Stenting Trial
Pittsburgh : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Port Matilda : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pottstown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Scranton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sellersville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tipton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Uniontown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wilkes-Barre : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
York : York Hospital
SuperNOVA Clinical Stenting Trial
York : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rhode Island
Cumberland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Providence : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Providence : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
South Carolina
Anderson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charleston : Medical University of South Carolina Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Charleston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charleston : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mt. Pleasant : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
N. Myrtle Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ninety Six : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orangeburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rock Hill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Spartanburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Varnville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Dakota
Rapid City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rapid City : Black Hills Cardiovascular
SuperNOVA Clinical Stenting Trial
Rapid City : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sioux Falls : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sioux Falls : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tennessee
Bristol : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Germantown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Johnson City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Johnson City : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Knoxville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Knoxville : Mercy Medical Center West
SuperNOVA Clinical Stenting Trial
Nashville : St. Thomas Research Institute, LLC
SuperNOVA Clinical Stenting Trial
Texas
Allen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Beaumont : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bedford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brownsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Corpus Christi/Texas : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Dallas : Veterans Affairs North Texas Health Care Systems
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Dallas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dallas : VA North Texas Health Care System
SuperNOVA Clinical Stenting Trial
Dallas : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Georgetown : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gonzales : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Harker Heights : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Houston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Houston : Baylor College of Medicine
Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions
Houston : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Irving : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lake Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leander : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Livingston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lufkin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Marshall : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
McKinney : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Odessa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pasadena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Plano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Plano : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Antonio : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Antonio : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Temple : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Victoria : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Waco : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Webster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Utah
Bountiful : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Draper : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Layton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salt Lake City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vermont
Virginia
Burke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Burke : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Danville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ettrick : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Falls Church : Inova Fairfax Hospital
SuperNOVA Clinical Stenting Trial
View More »
Norfolk : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Richmond : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Richmond : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Winchester : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Washington
Kirkland : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Olympia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Port Orchard : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Renton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Renton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Seattle : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seattle : Swedish Medical Center
SuperNOVA Clinical Stenting Trial
Seattle : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Seattle : University of Washington Coronary Atherosclerosis Research Lab
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Silverdale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Spokane : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tacoma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tacoma : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Walla Walla : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wenatchee : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Yakima : Yakima Heart Center
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Wisconsin
Madison : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wausau : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wauwatosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Argentina
Adrogue : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bahia Blanca : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bahía Blanca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Buenos Aires : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Buenos Aires : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Buenos Aries : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Caba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Caba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Caba : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cipolletti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ciudad Autonoma de Buenos Aires : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ciudad Autónoma de Buenos Aires : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cordoba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cordoba : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Córdoba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Corrientes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Corrientes : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Formosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Junin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
La Plata : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mar del Plata : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mar del Plata : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mendoza : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Posadas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Quilmes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ramos Mejia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rosario : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rosario : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Luis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Miguel de Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Nicolas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Salvador de Jujuy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Fe : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Fe : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Santiago del Estero : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tucuman : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Australia
Auchenflower : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ballarat : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bateman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bedford Park : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Caulfield South : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Coffs Harbour : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Concord : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Frankston : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Fremantle : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Garran : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Garran, ACT : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Geelong : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gosford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gosford : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Heidelberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hobart : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Joondalup : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Joondalup : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kippa Ring : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kogarah : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liverpool : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liverpool : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Malvern : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Melbourne : The Alfred
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
Milton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nedlands : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Perth : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sherwood : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Southport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austria
Feldbach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Graz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Linz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salzburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Stefan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Vienna : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vienne : Allgemeines Krankenhaus AKH
SuperNOVA Clinical Stenting Trial
Wien : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belgium
Aalst : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Aalst : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Antwerpen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bonheiden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bonheiden : Imelda Ziekenhuis
SuperNOVA Clinical Stenting Trial
View More »
Bonheiden : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Brasschaat : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bruxelles : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
De Pinte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dendermonde : AZ Sint-Blasius, Campus Dendermonde
SuperNOVA Clinical Stenting Trial
Genk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Genk : Ziekenhuis Oost Limburg
SuperNOVA Clinical Stenting Trial
Genk : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gent : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hasselt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hasselt : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Huy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
La Louvière : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Leuven : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leuven : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Liège : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mechelen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ottignies : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roeselaere : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tienen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Yvoir : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Brazil
Belem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belo Horizonte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belo Horizonte : Hospital Felicio Rocho
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Belo Horizonte : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Blumenau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Brasilia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Campinas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Campinas : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Campo Grande : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Curitiba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Curitiba : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Florianópolis : Clinica Coris Medicina Avançada /Baia Sul Medical Center
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Goiania : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Goiânia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Natal : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Passo Fundo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pelotas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pelotas : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Porto Alegre : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Porto Alegre : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Recife : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rio de Janeiro : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Salvador : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Santo Andre : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sao Jose do Rio Preto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
São José do Rio Preto : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sao Paulo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sao Paulo : Heart Institute
Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
São Paulo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
São Paulo : Hospital Santa Marcelina de São Paulo
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
São Paulo : Irmandade Santa Casa de Misericórdia de São Paulo
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
São Paulo : Instituto Dante Pazzanese de Cardiologia
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
São Paulo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Uberlândia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bulgaria
Dimitrovgrad : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pazardzhik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pleven : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pleven : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Plovdiv : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Plovdiv : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ruse : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sofia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sofia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Veliko Tarnovo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Canada
Ajax : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bay Roberts : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Brampton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cambridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Drummondville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Edmonton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gatineau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gatineau : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Granby : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greenfield Park : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Guelph : Guelph General Hospital
SuperNOVA Clinical Stenting Trial
Halifax : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Halifax : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hamilton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Joliette : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kelowna : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kitchener : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kitchener : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lachine : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Laval : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Levis : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lévis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Longueuil : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Loretteville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mississauga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mississauga : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Montreal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Montreal : Hospital Maisonneuve-Rosemont
SuperNOVA Clinical Stenting Trial
Montreal : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Montreal : Innovaderm Research Inc
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Mount Pearl : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Westminister : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
New Westminster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Westminster : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Newmarket : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oshawa : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ottawa : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Peterborough : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Quebec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Québec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Quebec City : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Saint Charles-Borromee : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sainte-Foy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saskatoon : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Scarborough : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sherbrooke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sherbrooke : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
St. John's : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ste-Foy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St-Hyacinthe : Clinique Médicale Dr Isabelle Delorme
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
St-Jean-sur-Richelieu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Surrey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Surrey : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Thetford Mines : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Thornhill : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Thunder Bay : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Toronto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Toronto : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Trois Rivières : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Truro : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Vancouver : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Victoria : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Winnipeg : Winnipeg Health Sciences Centre
SuperNOVA Clinical Stenting Trial
Winnipeg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chile
Santiago : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Talcahuano : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Viña del Mar : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
China
Beijing : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beijing : Cardiology department ,Beijing Anzhen hospital
Fluvastatin AmelIorates aTHerosclerosis Study
Beijing : Chinese PLA General Hospital
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
Beijing : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Changsha : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Guangzhou : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Guangzhou : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Haerbin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hang Zhou : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hangzhou : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jinan : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nanjing : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nanjing : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Shanghai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shanghai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shanghai : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tianjin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wuhan : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Xian : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Colombia
Baranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Barranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Barranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bogotá : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucaramanga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cartagena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cartegena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florida Blanca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Floridablanca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Czech Republic
Benesov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Broumov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Caslav : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chomutov : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chrudim : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Jihlava : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kladno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kladno : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kolin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kromeriz : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Louny : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Marianske lazne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Milevsko : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Most : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ostrava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pardubice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pisek : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Plzen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Prague 4 - Krc : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 11 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 2 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 2 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 2 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Praha 9 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Semily : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slany : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slany : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Svitavy : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tabor : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Usti nad Labem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Usti nad Orlici : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Usti nad Orlici : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Vyskov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Znojmo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Denmark
Aarhus : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Aarhus C : Dep. of Dermatology
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Esbjerg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Koebenhavn OE : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Silkeborg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Estonia
Parnu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tallinn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tallinn : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tartu : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Viljandimaa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Võru : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
France
Aix en Provence cedex 1 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Avignon : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Besançon Cedex : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bron Cedex : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Créteil : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Dijon : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lille Cedex : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Limoges : C.H.U. Dupuytren
The eMESH 1 Feasibility Study
Marseille cedex 5 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Metz Cedex 03 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nantes Cedex 1 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Narbonne Cedex : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nimes : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Paris : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Paris Cedex 13 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Paris Cedex 18 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pessac : Bordeaux University Hospital
The eMESH 1 Feasibility Study
Pessac cedex : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Roubaix : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Strasbourg cedex : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Toulouse Cedex 09 : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tourcoing : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Germany
Anderbeck : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Aschaffenburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bad Krozingen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bad Oeynhausen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Balve : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Berlin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Berlin : Center or Diagnostic Radiology and Minimally Invasive Therapy / Gefäßzentrum am JuedischenKrankenhaus
SuperNOVA Clinical Stenting Trial
Berlin : EV Krankenhaus Koningin Elisabeth
SuperNOVA Clinical Stenting Trial
Berlin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bernau : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Borna : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chemnitz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Deggingen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Delitzsch : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Dillingen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dorsten : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Dortmund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dresden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dresden : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Duisburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Düsseldorf : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ebersbach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Elsterwerda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Erlangen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Eschweiler : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Essen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Essen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Falkensee : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Flensburg : Ev. Luth. Diakonissenanstalt Flensburg
SuperNOVA Clinical Stenting Trial
Frankfurt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Frankfurt/M. : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Freiburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fulda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Giengen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Goch : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gueglingen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Haag : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haag : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Halle/'Saale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hamburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hamburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hannover : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Heidelberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heidelberg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Heidenau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heilbronn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Herford : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Herne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jerichow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kallstadt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kamp-Lintfort : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kelkheim : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Koblenz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Köln : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kuenzing : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kuenzing : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Leipzg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Leipzig : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leipzig : Herzzentrum Leipzig GmbH/Park Krankenhaus
SuperNOVA Clinical Stenting Trial
Leipzig : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lengerich : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lichtenfels : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ludwigshafen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lüneburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Magdeburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mainz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mainz : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mayen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Meissen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Muehldorf : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Muehldorf am Inn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Muehlhausen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Muenchen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mühlheim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Munich : Department of Neurology, TU Munich
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Münster : Universitätsklinikum Münster
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Neuhofen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Neunkirchen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Northeim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nürnberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oelde : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oschatz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Paderborn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Potsdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rednitzhembach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Reinfeld : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rhaunen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rostock : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rotenburg a.d. Fulda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rüdersdorf : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Schmiedeberg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Siegen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sulzbach-Rosenberg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ulm : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ulm : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wallerfing : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wedel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Weinheim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Weyhe-Leeste : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wiesbaden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Witten : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Witten : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wolmirstedt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greece
Agia Varvara, Athens : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Alexandroupolis : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Athens : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Athens - GR : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Chaidari : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chalikida : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chalkida : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Heraklion : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ioannina : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Magoula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Magoula, Elefsina : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Patras : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Patras : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Thessaloniki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Thessaloniki : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Voula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Voula / Athens : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Guatemala
Guatemala City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hong Kong
Hong Kong : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Shatin, New Territories : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hungary
Berettyóújfalu : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Budapest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Budapest : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Debrecen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gyula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Kistarcsa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komarom : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komárom : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Miskolc : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mosonmagyarovar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mosonmagyaróvár : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nyiregyháza : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pecs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sátoraljaújhely : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Szeged : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Székesfehérvár : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Szentes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Szikszó : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Szolnok : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Veszprem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zalaegerszeg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Iceland
Kopavogur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Reykjavik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
India
Ahmedabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ahmedabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ahmedabad : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bangalore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bangalore : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Bengaluru : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bikaner : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chennai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cochin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Coimbatore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ghaziabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Guntur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hyderabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hyderabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jaipur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jaipur : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kochi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lucknow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ludhiana : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Madurai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Manipal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mohali : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mysore : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nagpur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nashik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nellore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Delhi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Delhi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Delhi : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Patiala : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pune : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pune : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rajasthan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saket,Delhi : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Secunderabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Surat : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tirupati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vadodara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vadodara : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Varanasi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vijayawada : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vijayawada : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Vishakhapatnam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Italy
Ancona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ascoli Piceno : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bergamo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brescia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Carpi : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Casorate Primo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Catanzaro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chieti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chieti : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cona (Ferrara) : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cortona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cuneo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Fermo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Firenze : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Foggia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Massa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Milano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Milano : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Monserrato : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Napoli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Napoli : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Novara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Novara : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Palermo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Parma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Parma : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pavia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Piacenza : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pisa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pisa : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pozzilli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roma : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Daniele Del Friuli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Maria Capua Vetere : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sassari : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Treviglio : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Treviso : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Verona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Veruno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Japan
Aichi : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Amagasaki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bunkyo-ku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chiba : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chiyoda-ku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Fujioka-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fukuoka : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Funabashi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Higashiibaraki-gun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hitachi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hokkaido : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ichinomiya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Itabashi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kagoshima : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kanagawa : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kasuga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komatsushima : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kumamoto City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kusatsu-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kyoto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kyoto : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Matsudo-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nagano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nagano : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nagasaki : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nagoya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nishinomiya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ogaki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ogura-gun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oita : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Osaka : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Osaka : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sendai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sendai-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shiga : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Shizuoka : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Takamatsu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takarazuka-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takasaki-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takatsuki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tokorozawa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tokyo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Yokohama-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Korea, Republic of
Busan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Busan : Inje University Pusan Paik Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Cheongju : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Daegu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Daegu : Yeungnam University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
View More »
Dae-Gu : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Daejeon : Chungnam National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Daejon : Eulji University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Deagu : Kyungpook National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Gangnam-gu, Seoul : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gwangju : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gwangju : Chonnam National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Gwangju : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Iksan : Wonkwang University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Inchon : Inha University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
jeonju-si, Jeollabuk-Do : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pusan : Dong-A University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seo-gu Busan : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Seongnam-si Gyeonggi-do : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Seoul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seoul : Eulji Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Kyung Hee University Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Seoul Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Asan Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Boramae Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Uijeongbu-Si : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Uijeongbu-si Kyonggi-do : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wonju : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Latvia
Daugavplis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liepaja : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Riga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Riga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ventspils : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lebanon
Beirut : Rafic Hariri University Hospital
Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis
Lithuania
Alytus : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kaunas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kedainiai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Klaipeda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Panevezys : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Siauliai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vilnius : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mexico
Durango : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mexico : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
México D.F, : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Monterrey NL : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Netherlands
Alkmaar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amersfoort : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amstelveen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amsterdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amsterdam : Academic Medical Center
Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque
View More »
Amsterdam : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Amsterdamn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Apeldoorn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beverwijk : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Breda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Den Haag : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Deventer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Doetinchem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Doetinchem : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ede : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Eindhoven : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Enschede : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Goes : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gouda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Groningen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haarlem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Harderwijk : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Heerlen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hoofddorp : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hoorn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leeuwarden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leeuwarden : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Maastricht : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Meppel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nijmegen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rotterdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rotterdam : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sittard-geleen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sneek : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sneek : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tiel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tiel : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Utrecht : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Venlo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Zealand
Auckland : Auckland City Hospital
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
Auckland : Ascot Angiography
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Auckland : Auckland City Hospital
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Auckland : Mercy Angiography Unit, Ltd. Mercy Hospital
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Auckland : North Shore Hospital
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
View More »
Christchurch : Christchurch
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Christchurch : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Dunedin : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Grafton, Auckland : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hamilton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lower Hutt : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nelson : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Otahuhu : Middlemore Hospital
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Otahuhu, Auckland : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Palmerston North : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Takapuna, Auckland : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tauranga : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Timaru : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Whangarei : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Norway
Ålesund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bergen : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Elverum : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hamar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Harstad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Hønefoss : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lillehammer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Moss : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Moss : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nesttun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oslo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oslo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sandefjord : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skedsmokorset : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Stavanger : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tønsberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Trondheim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tynset : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pakistan
Karachi : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Korangi / Karachi : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lahore : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Multan : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rawalpindi Cantt : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Peru
Callao : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Jesus Maria : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lima : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Philippines
Ermita, Manila : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Manila : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Quezon City : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Juan : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Poland
Bialystok : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Bydgoszcz : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Gdansk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gdynia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gdynia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Kowanowko : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Krakow : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kraków : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Lódz : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Mielec : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Olawa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ostrow Wielkopolski : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Plonsk : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Poznan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Radom : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ruda Slaska : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Rumia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Siemianowice Slaskie : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Skierniewice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skierniewice : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Torun : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tychy : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Warszawa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Warszawa : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Warszawa : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wegrow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wloclawek : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Wroclaw : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Puerto Rico
Manati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mayaguez : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ponce : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Juan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Romania
Baia Mare : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Braila : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brasov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucharest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucharest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Bucharest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucharest : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj-Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Constanta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Craiova : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Craiova : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Deva : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Galati : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hunedoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Iasi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oradea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pitesti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sibiu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Targu-Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tg. Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Timisoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Timisoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Russian Federation
Barnaul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chelyabinsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ekaterinburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ekaterinburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Izhevsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Kemerovo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kemerovo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kirov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Krasnodar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Moscow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Moscow : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Novosibirsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Novosibirsk : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Omsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petrozavodsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ryazan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ryazan : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
S.-Petresburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Saint Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sankt-Peterburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saratov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sestroreck : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Smolensk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St Pertersburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
St. Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St.- Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St.-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St'Petersburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
St-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St-Petersburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tomsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tyumen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Yekaterinburg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Slovakia
Banska Bystrica : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bardejov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bratislava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bratislava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bratislava : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Brezno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dubnica nad Vahom : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dunajska Streda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Galanta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komarno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kosice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kosice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kosice : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Levice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lucenec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nitra : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nitra : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Nove Zamky : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Povazska Bystrica : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Presov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Presov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rimavska Sobota : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rimavska Sobota : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Svidnik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Trnava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Velky Krtis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zilina : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Africa
Bellville : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Bloemfontein : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bloemfontein : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cape Town : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Durban : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Johannesburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kempton Park : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kuils River : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lynnwood Ridge, Pretoria : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Olivedale : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Paarl : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Parktown : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Parktown West : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Parow : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pinelands : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pretoria : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Somerset West : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Soweto : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Umhlanga : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Verwoerdburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Spain
Alicante : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Granada : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Jerez de la Frontera : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lleida : Hospital Arnau de Vilanova
Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.
Madrid : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Malaga : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Marid : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Oviedo : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Pozuelo de Alarcón/Madrid : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Juan (Alicante) : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Sebastián : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
San Sebastián de los Reyes/Madrid : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Santander : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sevilla : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sta Coloma de Gramanet (Barcelona) : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Valdemoro/Madrid : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Sweden
Eksjö : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Göteborg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Göteborg : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kristianstad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Linköping : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Luleå : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lund : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Malmö : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Malmö : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Mölndal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Östersund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Östersund : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Skanör : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skelleftea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skene : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Stockholm : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Stockholm : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Uddevalla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Umeå : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Uppsala : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Vällingby : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Västerås : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Västerås : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Västervik : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Switzerland
Bern : University Hospital of Bern
The eMESH 1 Feasibility Study
Lausanne : Service de Chirurgie cardio-vasculaire CHUV
New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease
Taiwan
Changhua : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Changhua : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Ilan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kaohsiung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lin-Ko : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Niaosong Township : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taichung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taichung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taichung : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Tainan : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Taipei : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taipei : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taipei : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Taipei City : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Yungkang : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Thailand
Bangkok : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chiangmai : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Turkey
Istanbul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ukraine
Donetsk : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kharkiv : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Kyiv : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Lviv : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Odesa : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
View More »
Vinnytsia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Zaporizhzhia : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
United Kingdom
Atherstone : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Axbridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Barnet : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Basingstoke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Birmingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Bristol : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cambridge : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cardiff : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Carshalton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chelsea : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chertsey : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Chesterfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chichester : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Coatbridge : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cottingham : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Cumbernauld : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Dundee : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Exeter : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Glasgow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Glasgow : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hamilton : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Harrow : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Hertfordshire : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Irvine : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leicester : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liverpool : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Liverpool : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
London : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Motherwell : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Newcastle Upon Tyne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Newcastle-upon-Tyne : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Newport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Newport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Norwich : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nottingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nottingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oxford : CTSU, University of Oxford
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
Paisley : GSK Investigational Site
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Penzance : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sheffield : Northern General Hospital
SuperNOVA Clinical Stenting Trial
West Midlands : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Whitby : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Worcester : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
York : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
